Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Naphthoquinone SCHEMBL29778087 | 0.80 | IDO1 (0.42) | ALDH1A1KDM4EPOLBMAPTHTT | |
| Naphthoquinone SCHEMBL820053 | 0.80 | IDO1 (0.42) | ALDH1A1KDM4EPOLBMAPTHTT | |
| SCHEMBL18179634 | 0.76 | KDM4E (0.33) | ALDH1A1KDM4ERAPGEF4POLBMAPT | |
| SCHEMBL30472444 | 0.76 | ALDH1A1 (0.33) | ALDH1A1KDM4ERAPGEF4POLBMAPT | |
| SCHEMBL29151039 | 0.76 | ALDH1A1 (0.33) | ALDH1A1KDM4ERAPGEF4POLBMAPT | |
| SCHEMBL29445002 | 0.76 | ALDH1A1 (0.33) | ALDH1A1KDM4ERAPGEF4POLBMAPT | |
| SCHEMBL30860724 | 0.76 | ALDH1A1 (0.33) | ALDH1A1KDM4ERAPGEF4POLBMAPT | |
| SCHEMBL28476099 | 0.76 | ALDH1A1 (0.33) | ALDH1A1KDM4ERAPGEF4POLBMAPT | |
| SCHEMBL14024390 | 0.76 | ALDH1A1 (0.41) | ALDH1A1KDM4ERAPGEF4POLBMAPT | |
| Hydrochloric Acid SCHEMBL13721746 | 0.74 | ALDH1A1 (0.32) | ALDH1A1KDM4ERAPGEF4POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118406075-A | Silicon-containing polycyclic chromone skeleton compound, preparation method and application thereof | 遵义医科大学 | 2024-07-30 | — | — | CN | claimed |
| CN-111212647-B | Dihydro oxadiazinones | 拜耳股份有限公司 | 2024-05-14 | — | — | CN | claimed |
| CN-115557907-B | 2,4, 5-Trisubstituted 1,2, 4-triazolones as DHODH inhibitors | 拜耳股份有限公司 | 2024-12-06 | — | — | CN | disclosed |
| CN-118406075-A | Silicon-containing polycyclic chromone skeleton compound, preparation method and application thereof | 遵义医科大学 | 2024-07-30 | — | — | CN | disclosed |
| CN-111212647-B | Dihydro oxadiazinones | 拜耳股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-114921391-B | 4, 5-cyclic 1,2, 4-triazolones | 拜耳股份有限公司 | 2024-01-02 | — | — | CN | disclosed |
| CN-115557907-A | 2,4, 5-trisubstituted 1,2, 4-triazolones as DHODH inhibitors | 拜耳股份有限公司 | 2023-01-03 | — | — | CN | disclosed |
| CN-114921391-A | 4, 5-Cyclic 1,2, 4-triazolones | 拜耳股份有限公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-110023302-B | 2,4, 5-trisubstituted 1,2, 4-triazolones as DHODH inhibitors | 拜耳股份有限公司 | 2022-07-26 | — | — | CN | disclosed |
| CN-110248937-B | 4, 5-Cyclic 1,2, 4-triazolones | 拜耳股份有限公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-109661399-B | Cross-coupling method | 里科瑞尔姆IP控股有限责任公司 | 2021-09-07 | — | — | CN | disclosed |
| CN-112040951-A | Antibody Drug Conjugates (ADC) with NAMPT inhibitors | 拜耳股份公司 | 2020-12-04 | — | — | CN | disclosed |
| US-10077265-B2 | Substituted oxopyridine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-09-18 | — | — | US | disclosed |
| US-20170283412-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-05 | — | — | US | disclosed |
| US-9560850-B2 | Tetrazolinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-02-07 | — | — | US | disclosed |
| US-20150336908-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-11-26 | — | — | US | disclosed |
| EP-2675774-A1 | PRODUCTION METHOD OF OPTICALLY ACTIVE DIHYDROBENZOFURAN DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2013-12-25 | — | — | EP | disclosed |
| WO-2012111849-A1 | PRODUCTION METHOD OF OPTICALLY ACTIVE DIHYDROBENZOFURAN DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-23 | — | — | WO | disclosed |
| WO-2012004160-A1 | COMPOSITION FOR PRODUCING POLYMERS, (METH)ACRYLIC POLYMER, COATING AGENT, AND COATING | EVONIK RÖHM GMBH (DE) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10077265-B2 | Substituted oxopyridine derivatives | OGFOD1, PNPO, VASP | ALDH1A1 1944/4885KDM4E 1864/4885RAPGEF4 1772/4885 |
| US-20170283412-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | OGFOD1, PNPO, VASP | ALDH1A1 1944/4885KDM4E 1864/4885RAPGEF4 1772/4885 |
| US-20150336908-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | RTN3, CYP51A1, TCOF1 | ALDH1A1 2300/4885KDM4E 3146/4885RAPGEF4 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.